Tagged with VAT

R&D Gerardo Cárdenas Vogel, CEO of Innovare R&D, on transforming the company’s business model to benefit from drug development opportunities, Mexico as a world-class clinical trial destination, and new, innovative treatments as part of their partnership with the French biotech company LFB. When our colleagues met with you in February 2015,…

Generics Andreas Bosshard of Mepha-Teva in Switzerland describes Switzerland’s unique generics market, the quality of the Mepha-Teva brand, innovations within generics, and the company’s growth strategy within the Swiss market. It has been five years since the merger of Teva and Mepha in Switzerland, and curiously the brand name Mepha remains in…

Pharma Janssen’s company group chairman for Asia Pacific, Kris Sterkens distills the core elements of what it means to be a transformational medical innovator, while exclaiming how this characterization has molded the company’s patient-centric commitments across the region.  When several others have experienced drawback, what factors have best positioned Janssen for…

Switzerland Dr. Catherine Chammartin of the Swiss Federal Institute of Intellectual Property (IPI) describes the strong elements of an IP system and its contributions to innovation within Switzerland. The IPI registers intellectual property, advises on policy, provides IP services to the community, and is involved in educational endeavors. Could you start…

Innovation Professor Mark Ferguson, Director General of Science Foundation Ireland and Chief Scientific Advisor to the Government of Ireland, highlights Ireland’s recent spectacular success in fostering research and innovation; the government’s strategy to further promote Irish science, Innovation 2020; the priority of building academia-industry partnerships; and his mission to turn Ireland…

Pharma Raul Vivar, recently appointed GM of Eisai Mexico, describes the main achievements of the Japanese company in Mexico, the challenges that innovative companies face entering the Mexican market, and  the development path he will follow in order to foster growth. You took over the helm of the Mexican affiliate of…

Pharma Lundbeck Mexico GM Oscar Parra discusses raising awareness of depression in Mexico, Lundbeck’s innovative treatments for depression and Alzheimer’s, and managing to navigate the country’s regulatory process to ultimately benefit the patient. Lifestyle related illnesses are a major problem in Mexico, with 13 million people suffering from diabetes and 71…

Pharma Dr. Leisha Daly, Janssen Ireland country director and president of the Irish Pharmaceutical Healthcare Association (IPHA) discusses her presidency and the conclusion of a four-year agreement between IPHA and the Irish government on the supply of medicine. She then highlights Janssen’s leadership in Ireland in terms of ‘open-innovation’ and ‘beyond-the-pill’…

Health Professor Jürg Utzinger of the Swiss Tropical and Public Health Institute (Swiss TPH) emphasizes the importance of partnerships and sharing information for improving population health locally, nationally, and internationally. He comments on Swiss innovation, the clinical trials conducted at Swiss TPH, and the current publicity around the Zika virus.   You…

Pharma Janssen Switzerland’s Ludo Ooms highlights the strengths of the Swiss healthcare and life sciences sector including the efficiency of the government, a productive and well trained workforce, the national pricing system, and the climate for innovation; all factors which make Switzerland a strategic market for Johnson & Johnson and Janssen.…

Pharma With nearly €4 billion of capital investment in large molecule manufacturing underway, Ireland’s strategy to become a premier destination for biologics FDI has proven to be successful, according to BioPharmaChem Ireland director Matt Moran. Yet, Ireland today is much more than a manufacturing hub, and is well on its way to…

Pharma Teodoro Padilla, Executive Director at the Pharmaceutical and Healthcare Association of the Philippines, and Reiner Gloor, Advisor and Honorary Member, discuss the current objectives and goals of the association, how they are adapting to recent changes in the country’s healthcare landscape, and the impact of the rise of generics. To begin, could…